Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Hypersplenism, although a rare hematological complication seen in chronic kidney disease patients, poses a significant challenge for successful kidney transplantation due to potential complications such as cytopenias and inadequate immunosuppressive therapy. We present a 40-year old end-stage kidney disease patient on dialysis with hypersplenism who underwent a laparoscopic splenectomy prior to high immunological risk renal transplantation. Post-splenectomy, there was a remarkable improvement in cytopenias, and effective immunosuppressive therapy could be administered prior to renal transplantation. Splenectomy remains a valuable strategy for managing hypersplenism, ensuring correction of cytopenias, for optimal immunosuppression prior to kidney transplantation. Pre-transplant vaccination further mitigates the risk infections with capsulated organisms. Our case underscores the importance of a multidisciplinary approach in decision-making and highlights splenectomy as a safe and effective intervention to address cytopenias due to hypersplenism prior to renal transplantation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450904PMC
http://dx.doi.org/10.25259/ijn_268_23DOI Listing

Publication Analysis

Top Keywords

kidney transplantation
12
renal transplantation
12
kidney disease
8
immunosuppressive therapy
8
prior renal
8
transplantation
6
hypersplenism
5
splenectomy
4
splenectomy kidney
4
transplantation hypersplenism
4

Similar Publications

Purpose: Living donor kidney transplantation is a critical strategy to address the growing burden of end-stage kidney disease (ESKD) in Malaysia. Whilst living donation is generally safe, concerns remain regarding long-term donor outcomes. This study aimed to evaluate renal function and morbidity changes in living kidney donors 1 year post-donation, and to identify predictors of impaired kidney function.

View Article and Find Full Text PDF

Purpose: In 5-10% of cases, renal cancer extends into the venous system, particularly the inferior vena cava (IVC), which worsens prognosis. This study aims to assess morbidity, mortality, and oncological outcomes of patients treated surgically for renal cancer with IVC extension over a 30-year period, in two experienced centers.

Materials And Methods: This bicentric, retrospective study analyzed patients treated between 1988 and 2020 for renal cancer involving the IVC.

View Article and Find Full Text PDF

Out of chaos, comes tolerance: targeting the T cells driving antibody-mediated rejection.

Kidney Int

September 2025

Department of Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA; Transplant Center, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address:

View Article and Find Full Text PDF

Felzartamab: a magic bullet to treat microvascular rejection?

Kidney Int

September 2025

Immunopathology Research Laboratory, Department of Pathology, Boston, Massachusetts, USA; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article and Find Full Text PDF

Background: Cytomegalovirus (CMV) viremia is a critical concern and known by the presence of the virus DNA in the blood, which poses sever risks and develops many complications in immuno-compromised patients. When CMV is untreated, it can cause pneumonitis, colitis, hepatitis, and encephalitis. Current diagnosis relies on molecular methods with qPCR as the preferred method.

View Article and Find Full Text PDF